AU2012335596B2 - Methods of inhibiting tumor growth by antagonizing IL-6 receptor - Google Patents

Methods of inhibiting tumor growth by antagonizing IL-6 receptor Download PDF

Info

Publication number
AU2012335596B2
AU2012335596B2 AU2012335596A AU2012335596A AU2012335596B2 AU 2012335596 B2 AU2012335596 B2 AU 2012335596B2 AU 2012335596 A AU2012335596 A AU 2012335596A AU 2012335596 A AU2012335596 A AU 2012335596A AU 2012335596 B2 AU2012335596 B2 AU 2012335596B2
Authority
AU
Australia
Prior art keywords
ser
thr
val
pro
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012335596A
Other languages
English (en)
Other versions
AU2012335596A1 (en
Inventor
Li Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2012335596A1 publication Critical patent/AU2012335596A1/en
Application granted granted Critical
Publication of AU2012335596B2 publication Critical patent/AU2012335596B2/en
Priority to AU2018203666A priority Critical patent/AU2018203666A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2012335596A 2011-11-10 2012-11-09 Methods of inhibiting tumor growth by antagonizing IL-6 receptor Active AU2012335596B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018203666A AU2018203666A1 (en) 2011-11-10 2018-05-24 Methods of inhibiting tumor growth by antagonizing IL-6 receptor

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161557939P 2011-11-10 2011-11-10
US61/557,939 2011-11-10
US201261609968P 2012-03-13 2012-03-13
US61/609,968 2012-03-13
US201261613538P 2012-03-21 2012-03-21
US61/613,538 2012-03-21
PCT/US2012/064311 WO2013071016A2 (en) 2011-11-10 2012-11-09 Methods of inhibiting tumor growth by antagonizing il-6 receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018203666A Division AU2018203666A1 (en) 2011-11-10 2018-05-24 Methods of inhibiting tumor growth by antagonizing IL-6 receptor

Publications (2)

Publication Number Publication Date
AU2012335596A1 AU2012335596A1 (en) 2014-05-22
AU2012335596B2 true AU2012335596B2 (en) 2018-05-17

Family

ID=47179020

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012335596A Active AU2012335596B2 (en) 2011-11-10 2012-11-09 Methods of inhibiting tumor growth by antagonizing IL-6 receptor
AU2018203666A Abandoned AU2018203666A1 (en) 2011-11-10 2018-05-24 Methods of inhibiting tumor growth by antagonizing IL-6 receptor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018203666A Abandoned AU2018203666A1 (en) 2011-11-10 2018-05-24 Methods of inhibiting tumor growth by antagonizing IL-6 receptor

Country Status (20)

Country Link
US (3) US20130122003A1 (https=)
EP (1) EP2776468B1 (https=)
JP (3) JP6144689B2 (https=)
KR (1) KR101718748B1 (https=)
CN (1) CN103930443B (https=)
AR (1) AR088671A1 (https=)
AU (2) AU2012335596B2 (https=)
BR (1) BR112014011211A2 (https=)
CA (1) CA2853836C (https=)
IL (2) IL231854A (https=)
IN (1) IN2014CN02923A (https=)
JO (1) JO3370B1 (https=)
MX (1) MX357837B (https=)
MY (1) MY163953A (https=)
RU (1) RU2648150C2 (https=)
SG (1) SG11201401286QA (https=)
TW (3) TW201716776A (https=)
UY (1) UY34444A (https=)
WO (1) WO2013071016A2 (https=)
ZA (1) ZA201402414B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
WO2015000181A1 (zh) * 2013-07-05 2015-01-08 华博生物医药技术（上海）有限公司 新型重组融合蛋白及其制法和用途
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
MX379491B (es) * 2014-06-28 2025-03-10 Kodiak Sciences Inc Antagonistas duales de factor de crecimiento derivado de plaquetas (pdgf)/factor de crecimiento endotelial vascular (vegf)
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3303398A1 (en) * 2015-05-29 2018-04-11 Merrimack Pharmaceuticals, Inc. Combination cancer therapies
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
MX2020009152A (es) * 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
US11965176B2 (en) 2018-03-14 2024-04-23 Hunan Siweikang Therapeutics Co. Ltd Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy
CN108567981A (zh) * 2018-07-17 2018-09-25 漯河医学高等专科学校 白细胞介素-6的拮抗剂在制备抑制Notch-1蛋白表达、治疗胰腺癌的药物中的应用
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
US20220096548A1 (en) * 2019-01-07 2022-03-31 Hunan Siweikang Therapeutics Co. Ltd. Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CA3211803A1 (en) * 2021-02-27 2022-09-01 Eluminex Biosciences (Suzhou) Limited Antibody fusion proteins targeting il-6 receptor and angiogenic factors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582298B2 (en) * 2006-06-02 2009-09-01 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
EP0628639B1 (en) 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
EP0800829B2 (en) 1994-12-29 2012-07-25 Chugai Seiyaku Kabushiki Kaisha Use of a pm-1 antibody or of a mh 166 antibody for enhancing the anti-tumor effect of cisplatin or carboplatin
US5795695A (en) 1996-09-30 1998-08-18 Xerox Corporation Recording and backing sheets containing linear and cross-linked polyester resins
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
CN100523187C (zh) * 1999-06-08 2009-08-05 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US6670373B1 (en) 1999-10-07 2003-12-30 Eli Lilly And Company Compounds and method for inhibiting MRP1
WO2002036164A1 (en) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
ES2393485T3 (es) * 2003-07-02 2012-12-21 Innate Pharma Anticuerpos del receptor de NK pan-kir2dl y su uso en diagnóstico y terapia
KR101193708B1 (ko) 2003-10-17 2012-10-22 추가이 세이야쿠 가부시키가이샤 중피종 치료제
TW200803894A (en) 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
WO2008154927A1 (en) * 2007-06-21 2008-12-24 Genmab A/S Novel methods for treating egfr-associated tumors
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
CA2744400C (en) * 2008-11-25 2019-01-15 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582298B2 (en) * 2006-06-02 2009-09-01 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor

Also Published As

Publication number Publication date
AU2018203666A1 (en) 2018-06-14
CA2853836A1 (en) 2013-05-16
US9409990B2 (en) 2016-08-09
EP2776468B1 (en) 2018-01-24
KR20140095481A (ko) 2014-08-01
US20140322215A1 (en) 2014-10-30
US20170022279A1 (en) 2017-01-26
IL248620A0 (en) 2016-12-29
JO3370B1 (ar) 2019-03-13
JP2018083841A (ja) 2018-05-31
TWI604852B (zh) 2017-11-11
BR112014011211A2 (pt) 2017-04-25
ZA201402414B (en) 2015-03-25
CN103930443A (zh) 2014-07-16
MX2014004886A (es) 2014-07-09
EP2776468A2 (en) 2014-09-17
WO2013071016A2 (en) 2013-05-16
TW201806620A (zh) 2018-03-01
AU2012335596A1 (en) 2014-05-22
JP6283754B2 (ja) 2018-02-21
IN2014CN02923A (https=) 2015-07-03
CN103930443B (zh) 2017-08-04
JP6144689B2 (ja) 2017-06-07
TW201716776A (zh) 2017-05-16
CA2853836C (en) 2019-07-23
SG11201401286QA (en) 2014-05-29
MY163953A (en) 2017-11-15
US20130122003A1 (en) 2013-05-16
TW201332569A (zh) 2013-08-16
RU2014118739A (ru) 2015-12-20
UY34444A (es) 2013-05-31
KR101718748B1 (ko) 2017-03-22
IL231854A (en) 2016-11-30
MX357837B (es) 2018-07-26
JP2014534237A (ja) 2014-12-18
RU2648150C2 (ru) 2018-03-22
IL231854A0 (en) 2014-05-28
JP2017095489A (ja) 2017-06-01
AR088671A1 (es) 2014-06-25
WO2013071016A3 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
AU2012335596B2 (en) Methods of inhibiting tumor growth by antagonizing IL-6 receptor
US11655291B2 (en) Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin A
KR102338453B1 (ko) Ｖｅｇｆ 길항제와 항-ｃｔｌａ-4 항체의 조합물을 포함하는 조성물 및 방법
KR20220007086A (ko) T1dm 및 췌도염의 치료에 사용하기 위한 항-cd40 항체
AU2019226551A1 (en) Methods for altering body composition
HK1197681B (en) Methods of inhibiting tumor growth by antagonizing il-6 receptor
HK1197681A (en) Methods of inhibiting tumor growth by antagonizing il-6 receptor
HK1202559B (en) Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)